Bristol-Myers Squibb Company
BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS

Last updated:

Abstract:

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CR.sub.4a or N; Y is CR.sub.4b or N; Z is CR.sub.4d or N; provided that zero or 1 of X, Y, and Z is N; and R.sub.1, R.sub.2, R.sub.3, R.sub.4a, R.sub.4b, R.sub.4c, and R.sub.4d are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer. ##STR00001##

Status:
Application
Type:

Utility

Filling date:

5 Aug 2020

Issue date:

8 Sep 2022